Puma Biotechnology Raises Guidance on NERLYNX Strength

Puma Biotechnology (PBYI) reported strong second-quarter results, with revenue rising 7.8% year-over-year to $56.5 million and net income climbing 39.9% to $8.19 million. The company’s Non-GAAP EPS of $0.19 significantly exceeded analyst estimates, beating by $0.12. Management raised full-year guidance, projecting total revenue between $224 million and $231 million, reflecting robust demand for its core product, NERLYNX.

Revenue

The total revenue of Puma Biotechnology increased by 7.8% to $56.50 million in 2026 Q2, up from $52.44 million in 2025 Q2. Product revenue, net, accounted for the vast majority of this growth at $53.56 million, while royalty revenue contributed an additional $2.94 million.

Earnings/Net Income

Puma Biotechnology's EPS rose 33.3% to $0.16 in 2026 Q2 from $0.12 in 2025 Q2, marking continued earnings growth. Meanwhile, the company's profitability strengthened with net income of $8.19 million in 2026 Q2, marking 39.9% growth from $5.86 million in 2025 Q2. This performance indicates robust operational efficiency and strong demand for its commercial products.

Price Action

The stock price of Puma Biotechnology has edged up 1.25% during the latest trading day, has edged up 2.92% during the most recent full trading week, and has edged up 2.01% month-to-date.

Post Earnings Price Action Review

I can backtest the PBYI revenue-beat → 30-day hold strategy, but I cannot verify the earnings dates or revenue beat history from the sources available to me right now, so I can only give you a price-history sanity check for now.From the latest available price history, PBYI has been in a strong uptrend over the last year, closing at $3.12 on January 2, 2025 and $8.69 on August 7, 2026, for a 184.92% total move over that period.visual{"uuid":"1c8778f5-5a33-4d52-b9b8-8a70d58e894c","type":"model"}

Trend and volatility are elevated, with the stock trading as high as $8.19 on June 29, 2026, before pulling back to $7.48 on July 23, 2026, and rebounding to $8.69 on August 7, 2026. This pattern matters because earnings can amplify volatility; if the revenue beat happens on a gap-up day, the first 30 days may already be partially priced in. To properly backtest “buy on revenue beat, hold 30 days,” specific earnings dates and revenue beat/miss history or a CSV file are required to compute win rate and expectancy. Based on price action alone, PBYI has had a strong run, but that does not guarantee earnings will continue to reward a 30-day hold. For an earnings-driven strategy, the timing of the beat relative to the tape matters more than the long-term chart. A second backtest for the opposite case—buying on revenue miss—could reveal whether PBYI is mainly a beat-driven momentum name or a story-driven microcap.

CEO Commentary

Alan H. Auerbach, Chairman, Chief Executive Officer and President of Puma, highlighted strong commercial execution and year-over-year demand growth for NERLYNX during the second quarter. He expressed satisfaction with clinical progress across development programs, specifically alisertib. The leadership team remains focused on sustaining commercial momentum in the second half of the year while advancing alisertib in ALISCA® trials for HER2-negative, hormone receptor-positive metastatic breast cancer and small cell lung cancer. Auerbach emphasized continued dedication to both commercial excellence and clinical advancement, reflecting an optimistic outlook driven by product sales increases and strategic pipeline progression without citing external market factors.

Guidance

Puma raised its 2026 financial outlook, projecting full-year net product revenue between $205 million and $209 million, up from the previous range of $202 million to $206 million. Full-year royalty revenue is expected to be $19 million to $22 million, compared to the prior $20 million to $23 million estimate. Consequently, total revenue guidance was increased to $224 million–$231 million from $222 million–$229 million. The company now anticipates full-year net income of $17 million to $20 million, revising upward from the previous $16 million to $19 million range. For the third quarter, net product revenue is guided at $54 million–$56 million, with total revenue expected between $56 million and $59 million.

Additional News

In addition to its financial results, Puma Biotechnology announced the approval of inducement restricted stock unit (RSU) awards under Nasdaq Listing Rule 5635(c)(4). On August 3, 2026, the Compensation Committee granted 35,375 shares of common stock to five new non-executive employees. These RSUs vest over a three-year period, with one-third vesting on the first anniversary of the award’s commencement date, August 1, 2026, and one-sixth vesting every six months thereafter. This equity grant is part of the company’s 2017 Employment Inducement Incentive Award Plan, designed to attract top talent. The company continues to focus on developing innovative cancer care products, including NERLYNX® and the Aurora kinase A inhibitor alisertib. Recent clinical advancements include the initiation of ALISCA®-Lung1 for small cell lung cancer and ALISCA®-Breast1 for breast cancer, signaling ongoing commitment to expanding its pipeline beyond its core commercial offerings.